TTI-621 (SIRPαFc): A CD47-Blocking Innate Immune Checkpoint Inhibitor with Broad Antitumor Activity and Minimal Erythrocyte Binding.

Autor: Petrova PS; Trillium Therapeutics Inc., Mississauga, Ontario, Canada., Viller NN; Trillium Therapeutics Inc., Mississauga, Ontario, Canada., Wong M; Trillium Therapeutics Inc., Mississauga, Ontario, Canada., Pang X; Trillium Therapeutics Inc., Mississauga, Ontario, Canada., Lin GH; Trillium Therapeutics Inc., Mississauga, Ontario, Canada., Dodge K; Trillium Therapeutics Inc., Mississauga, Ontario, Canada., Chai V; Trillium Therapeutics Inc., Mississauga, Ontario, Canada., Chen H; Trillium Therapeutics Inc., Mississauga, Ontario, Canada., Lee V; Trillium Therapeutics Inc., Mississauga, Ontario, Canada., House V; Trillium Therapeutics Inc., Mississauga, Ontario, Canada., Vigo NT; Trillium Therapeutics Inc., Mississauga, Ontario, Canada., Jin D; Trillium Therapeutics Inc., Mississauga, Ontario, Canada., Mutukura T; Trillium Therapeutics Inc., Mississauga, Ontario, Canada., Charbonneau M; Trillium Therapeutics Inc., Mississauga, Ontario, Canada., Truong T; Trillium Therapeutics Inc., Mississauga, Ontario, Canada., Viau S; Trillium Therapeutics Inc., Mississauga, Ontario, Canada., Johnson LD; Trillium Therapeutics Inc., Mississauga, Ontario, Canada., Linderoth E; Trillium Therapeutics Inc., Mississauga, Ontario, Canada., Sievers EL; Trillium Therapeutics Inc., Mississauga, Ontario, Canada., Maleki Vareki S; London Regional Cancer Program, London Health Sciences Centre, Lawson Heath Research Institute, London, Ontario, Canada.; Department of Oncology, University of Western Ontario, London, Ontario, Canada., Figueredo R; London Regional Cancer Program, London Health Sciences Centre, Lawson Heath Research Institute, London, Ontario, Canada.; Department of Oncology, University of Western Ontario, London, Ontario, Canada., Pampillo M; London Regional Cancer Program, London Health Sciences Centre, Lawson Heath Research Institute, London, Ontario, Canada., Koropatnick J; London Regional Cancer Program, London Health Sciences Centre, Lawson Heath Research Institute, London, Ontario, Canada.; Department of Oncology, University of Western Ontario, London, Ontario, Canada., Trudel S; Princess Margaret Cancer Center, University Health Network (UHN), Toronto, Ontario, Canada., Mbong N; Princess Margaret Cancer Center, University Health Network (UHN), Toronto, Ontario, Canada., Jin L; Princess Margaret Cancer Center, University Health Network (UHN), Toronto, Ontario, Canada., Wang JC; Princess Margaret Cancer Center, University Health Network (UHN), Toronto, Ontario, Canada.; Division of Medical Oncology and Hematology, Department of Medicine, UHN, and Department of Medicine, University of Toronto, Toronto, Ontario, Canada., Uger RA; Trillium Therapeutics Inc., Mississauga, Ontario, Canada. bob@trilliumtherapeutics.com.

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2017 Feb 15; Vol. 23 (4), pp. 1068-1079. Date of Electronic Publication: 2016 Nov 17.